<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-KU0KIXSI/73a-1a09431682ccef-938a014-0e-2547bb/PDF"><dcterms:extent>1317 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-KU0KIXSI/405840ba-0ac7-4921-a738-e31c2b369e1f/TEXT"><dcterms:extent>24 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2022-2025"><edm:begin xml:lang="en">2022</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-KU0KIXSI"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q" /><dcterms:issued>2022</dcterms:issued><dc:creator>Frlic, Tjaša</dc:creator><dc:creator>Korbar, Karmen</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">str. 26-30</dc:format><dc:identifier>COBISSID_HOST:122888963</dc:identifier><dc:identifier>ISSN:2820-5014</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-KU0KIXSI</dc:identifier><dc:language>en</dc:language><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Fakulteta za farmacijo, ŠSSFD</dc:publisher><dcterms:isPartOf xml:lang="sl">Placebo</dcterms:isPartOf><dc:subject xml:lang="en">autoantibodies</dc:subject><dc:subject xml:lang="sl">Avtoimunske bolezni</dc:subject><dc:subject xml:lang="sl">avtoprotitelesa</dc:subject><dc:subject xml:lang="en">complete blood count</dc:subject><dc:subject xml:lang="sl">ELISA</dc:subject><dc:subject xml:lang="sl">encimsko-imunokemijske metode</dc:subject><dc:subject xml:lang="en">enzyme immunochemical methods</dc:subject><dc:subject xml:lang="en">indirect immunofluorescence</dc:subject><dc:subject xml:lang="sl">indirektna imunofluorescenca</dc:subject><dc:subject xml:lang="en">inflammatory markers</dc:subject><dc:subject xml:lang="sl">krvna slika</dc:subject><dc:subject xml:lang="sl">Laboratorijske preiskave</dc:subject><dc:subject xml:lang="sl">označevalci vnetja</dc:subject><dc:subject xml:lang="sl">Revmatične bolezni</dc:subject><dcterms:temporal rdf:resource="2022-2025" /><dc:title xml:lang="sl">Laboratorijske preiskave za odkrivanje revmatičnih bolezni avtoimunskega izvora|</dc:title><dc:description xml:lang="sl">Disorders are part of rheumatic diseases with predominant inflammation and/or autoimmune signs. Autoimmune diseases are very complex and there is not one specific test that can diagnose autoimmune disease conclusively. Testing of mentioned diseases usually starts with basic hematological and biochemical tests. Important tests are hemogram and biochemical test for inflammatory biomarkers, especially sedimentation and C-reactive protein (CRP). With them we can confirm presence of inflammatory process in patient’s body, which is characteristic for reumatic autoimmune diseases. Next test performed is usually test on HEp-2 cells, that is based on indirect immufluorescence. This is a reference method for detection of antinuclear antibodies. Furthermore, enzyme immunochemical methods are mostly used for quantification of specific autoantibodies. Some of them are specific for one disease, but interpretation of test results is by most of them very complicated. During the diagnosis, it is important to consider clinical status of the patient as well</dc:description><dc:description xml:lang="sl">Vnetne revmatične bolezni in sistemske bolezni vezivnega tkiva sta skupini revmatskih bolezni, kjer prevladuje vnetje in/ali avtoimunsko dogajanje. Avtoimunske bolezni so zelo kompleksne bolezni, zato ne obstaja samo en test, s katerim bi lahko podali diagnozo. Laboratorijsko testiranje zgoraj omenjenih bolezni se običajno začne z osnovnimi hematološkimi in biokemijskimi preiskavami. Pomembna testa sta hemogram in določanje označevalcev vnetja, predvsem sedimentacije in C-reaktivnega proteina (CRP), s katerimi potrdimo prisotnost vnetnega procesa v telesu, ki je značilen za revmatske avtoimunske bolezni. Pri sumu na avtoimunsko bolezen sledi presejalni test HEp-2, katerega osnova je indirektna imunofluorescenca in je referenčna metoda za določanje protiteles proti znotrajceličnim antigenom jedra, citoplazme in celice v delitvi. Sledi diferencialna diagnostika, kjer se določajo specifična avtoprotitelesa, predvsem z encimsko-imunokemijskimi metodami. Nekatera avtoprotitelesa so značilna za določeno bolezen, vendar je pri večini avtoimunskih bolezni interpretacija rezultatov testov zelo zapletena. Poleg njih je treba vselej spremljati tudi klinično sliko bolnika</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-KU0KIXSI"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-KU0KIXSI" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-KU0KIXSI/73a-1a09431682ccef-938a014-0e-2547bb/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:dataProvider xml:lang="en">National and University Library of Slovenia</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-KU0KIXSI/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-KU0KIXSI" /></ore:Aggregation></rdf:RDF>